<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2020-5-120-127.</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-5611</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАБОЛЕВАНИЯ КИШЕЧНИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>BOWEL DISEASES</subject></subj-group></article-categories><title-group><article-title>Синергизм компонентов как основной подход к формированию пробиотического комплекса</article-title><trans-title-group xml:lang="en"><trans-title>Synergism of components as the main approach to creation of a probiotic complex</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6589-7654</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ших</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shikh</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ших Евгения Валерьевна - доктор медицинских наук, профессор, заведующая кафедрой клинической фармакологии и пропедевтики внутренних болезней.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Evgenia V. Shikh - Dr. of Sci. (Med.), Professor, Head of Chair for Clinical Pharmacology and Propaedeutics of Internal Diseases.</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991</p></bio><email xlink:type="simple">chih@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2013-3455</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соловьева</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Solovieva</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Соловьева Светлана Александровна - кандидат медицинских наук, ассистент, кафедра клинической фармакологии и пропедевтики внутренних болезней.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Svetlana A. Solovieva - Cand. of Sci. (Med.), Teaching Assistant, Chair for Clinical Pharmacology and Propaedeutics of Internal Diseases.</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991</p></bio><email xlink:type="simple">s.solovieva@outlook.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5896-1419</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Perkov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Перков Александр Владимирович - ассистент, кафедра клинической фармакологии и пропедевтики внутренних болезней.</p><p>119991, Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>Aleksandr V. Perkov - Teaching Assistant, Chair for Clinical Pharmacology and Propaedeutics of Internal Diseases.</p><p>8, Bldg. 2, Trubetskaya St., Moscow, 119991</p></bio><email xlink:type="simple">sasha1971per@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Moscow State Medical University named after I.M. Sechenov (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>05</month><year>2020</year></pub-date><volume>0</volume><issue>5</issue><fpage>120</fpage><lpage>127</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ших Е.В., Соловьева С.А., Перков А.В., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Ших Е.В., Соловьева С.А., Перков А.В.</copyright-holder><copyright-holder xml:lang="en">Shikh E.V., Solovieva S.A., Perkov A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/5611">https://www.med-sovet.pro/jour/article/view/5611</self-uri><abstract><p>Разработка пробиотической продукции, содержащей несколько штаммов: Bifidombacterium lactis BI-04, Lactobacillus acidophilus La-14 и Lactobacillus rhamnosus Lr-32, является перспективным направлением, т. к. увеличивает потенциал профилактического воздействия. Согласно результатам экспериментальных исследований in vitro, штаммы Lactobacillus acidophilus La-14, L. rhamnosus Lr-32, Bifidombacterium lactis BI-04 устойчивы к условиям низкого рН и выживают при наличии желчи в концентрациях, присутствующих в двенадцатиперстной кишке. Демонстрируют высокую адгезию к линиям эпителиальных клеток человека - Caco-2 и HT-29. В экспериментах invitro доказано ингибирующее действие штаммов L. acidophilusLa-14, L. rhamnosusLr-32 на следующие патогены: Salmonellatyphimurium, Staphylococcusaureus, Escherichiacoli, Listeriamonocytogenes. Комбинация пробиотических штаммов с подтвержденными эффектами invitro и invivo с пребиотиком и витаминами группы В является рациональной. Дополнительные благоприятные условия в виде наличия питательной среды (пребиотик), достаточное энергообеспечение (коферментные витамины) способствуют повышению колонизационного потенциала. Инулин и витамины группы В обладают собственной активностью, которая синергична с активностью пробиотических микроорганизмов. Витамин B12 имеет в своей структуре порфириноподобное, или корриновое, кольцо, связанное с атомом кобальта четырьмя координационными связями, и является представителем группы корриноидов. Микроорганизмы, заселяющие желудочнокишечный тракт человека, в качестве кофакторов используют экзогенно поступившие корриноиды кобаламина. Целесообразно сопровождать применение пробиотиков дополнительным экзогенным поступлением в организм витамина В12, т. к. микробные сообщества кишечника являются вероятными конкурентами в потреблении кобаламина. Рациональный подбор компонентов способствует максимальной реализации потенциальных профилактических эффектов пробиотических микроорганизмов.</p></abstract><trans-abstract xml:lang="en"><p>Development of probiotic products containing several strains: Bifidumbacterium lactis BI-04, Lactobacillus acidophilus La-14 and Lactobacillus rhamnosus Lr-32, is an upcoming trend, as it builds capacity of preventive treatment. According to the results of in vitro experimental studies, the strains of Lactobacillus acidophilus La-14, L. rhamnosus Lr-32, Bifidumbacterium lactis BI-04 are resistant to low pH conditions and survive in the concentrations of bile salts in the small intestine. Demonstrate high adhesion to the human epithelial cell lines - Caco-2 and HT-29. In vitro experiments have shown the inhibitory effect of strains L. acidophilus La-14, L. rhamnosus Lr-32 on the following pathogens: Salmonella typhimurium, Staphylococcus aureus, Escherichia coli, Listeria monocytogenes. The probiotic strains with in vitro and in vivo confirmed effects combined a prebiotic and B vitamins is considered a rational combination. Additional favourable conditions in the form of nutrient medium (prebiotic), sufficient energy supply (coenzyme vitamins) contribute towards the increase of colonization potential. Inulin and B vitamins have their own activity, which is synergistic with the probiotic microorganism activity. Vitamin B12 has a porphyrin-like or corrine ring in its structure, which is linked to the cobalt atom by four coordination bonds and is representative of corrinoids group. Microorganisms inhabiting the GI tract use exogenously produced cobalamin corrinoids as cofactors. It is appropriate to add the use of probiotics with additional exogenous intake of vitamin B12, as microbial communities of the human gut are likely competitors in the consumption of cobalamin. The rational selection of components contributes to the maximum implementation of potential preventive effects of probiotic microorganisms.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>бифидобактерии</kwd><kwd>лактобактерии</kwd><kwd>инулин</kwd><kwd>кобаламин</kwd><kwd>корриноиды</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bifidobacteria</kwd><kwd>lactobacilli</kwd><kwd>inulin</kwd><kwd>cobalamin</kwd><kwd>corrinoids</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Никонов Е.Л., Попова Е.Л. (ред.). Микробиота. М.: Медиа Сфера; 2019. 255 с. Режим доступа: https//www.eLibrary.ru/item.asp?id=38244535.</mixed-citation><mixed-citation xml:lang="en">Nikonov E.L., Popova E.L. (ed.). Microbiota. Moscow: Media Sfera; 2019. 255 с. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=38244535.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">VenugopaLan V., Shriner K.A., Wong-Beringer A. Regulatory Oversight and Safety of Probiotic Use. Emerging Infectious Diseases. 2010;16(11):1661-1665. doi: 10.3201/eid1611.100574.</mixed-citation><mixed-citation xml:lang="en">Venugopalan V., Shriner K.A., Wong-Beringer A. Regulatory Oversight and Safety of Probiotic Use. Emerging Infectious Diseases. 2010;16(11):1661-1665. doi: 10.3201/eid1611.100574.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Binns N. Probiotics, Prebiotics and the gut microbiota. Brussels; 2013. 32 p. Available at: https://iLsi.org/europe/wp-content/upLoads/sites/3/2016/05/Prebiotics-Probiotics.pdf.</mixed-citation><mixed-citation xml:lang="en">Binns N. Probiotics, Prebiotics and the gut microbiota. Brussels; 2013. 32 p. Available at: https://ilsi.org/europe/wp-content/uploads/sites/3/2016/05/Prebiotics-Probiotics.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Andoh A. Physiological RoLe of Gut Microbiota for Maintaining Human Health. Digestion. 2016;93(3):176-181. doi: 10,1159/000444066.</mixed-citation><mixed-citation xml:lang="en">Andoh A. Physiological Role of Gut Microbiota for Maintaining Human Health. Digestion. 2016;93(3):176-181. doi: 10,1159/000444066.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Потапов В.А. Пробиотики в гинекологии. Очередная мода или осознанная необходимость (аналитический обзор). З турботою про ж'!нку. 2015;(1):10-15. Режим доступа: https://organosyn.com.ua/down-Loads/0000/0623/articLe_8_5.pdf.</mixed-citation><mixed-citation xml:lang="en">Potapov V.A. Probiotics in gynecology: fashion or aware of the need (market watch). Z turbotoyu pro zhinku = With the care of a woman. 2015;(1):10-15. (In Russ.) Available at: https://organosyn.com.ua/down-loads/0000/0623/article_8_5.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gomaa A., Verghese M., Herring J. Inhibition of AntimicrobiaL Resistant SaLmoneLLa HeideLberg by a Synbiotic Combination of Prebiotics and Probiotics in an in Vitro ModeL (P20-011-19). Curr Dev Nutr. 2019;3(1):nzz040. doi: 10.1093/cdn/nzz040.P20-011-19.</mixed-citation><mixed-citation xml:lang="en">Gomaa A., Verghese M., Herring J. Inhibition of Antimicrobial Resistant Salmonella Heidelberg by a Synbiotic Combination of Prebiotics and Probiotics in an in Vitro Model (P20-011-19). Curr Dev Nutr. 2019;3(1):nzz040. doi: 10.1093/cdn/nzz040.P20-011-19.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lyra A., HiLLiLa M., Huttunen T., Mannikko S., TaaLikka M., TenniLaet J. et aL. IrritabLe boweL syndrome symptom severity improves equaLLy with probiotic and pLacebo. World J Gastroenterol. 2016;22(48):10631-10642. doi: 10.3748/wjg.v22.i48.10631.</mixed-citation><mixed-citation xml:lang="en">Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennilaet J. et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol. 2016;22(48):10631-10642. doi: 10.3748/wjg.v22.i48.10631.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ouwehand A.C., DongLian C., Weijian X., Stewart M., Ni J., Stewart T., MiLLer L.E. Probiotics reduce symptoms of antibiotic use in a hospitaL setting: a randomized dose response study. Vaccine. 2014;32(4):458-463. doi: 10.1016/j.vaccine.2013.11.053.</mixed-citation><mixed-citation xml:lang="en">Ouwehand A.C., DongLian C., Weijian X., Stewart M., Ni J., Stewart T., Miller L.E. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463. doi: 10.1016/j.vaccine.2013.11.053.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Forssten S., Evans M., WiLson D., Ouwehand A.C. InfLuence of a probiotic mixture on antibiotic induced microbiota disturbances. World J Gastroenterol. 2014;20(33):11878-11885. doi: 10.3748/wjg.v20.i33.11878.</mixed-citation><mixed-citation xml:lang="en">Forssten S., Evans M., Wilson D., Ouwehand A.C. Influence of a probiotic mixture on antibiotic induced microbiota disturbances. World J Gastroenterol. 2014;20(33):11878-11885. doi: 10.3748/wjg.v20.i33.11878.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guarner F., Khan A.G., Garisch J., Fedorak R., GangL A., Garisch J. и соавт. Пробиотики и пребиотики. Глобальные практические рекомендации Всемирной Гастроэнтерологической Организации; 2017. 37 с. Режим доступа: https://www.worLdgastroenteroLogy.org/UserFiLes/fiLe/guideLines/ probiotics-and-prebiotics-russian-2017.pdf.</mixed-citation><mixed-citation xml:lang="en">Guarner F., Khan A.G., Garisch J., Fedorak R., Gangl A., Garisch J. et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. 2017. 37 p. Available at: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Turroni S., VitaLi B., BendazzoLi C., CandeLa M., Gotti R., Federici F., Pirovano F., Brigid P OxaLate consumption by LactobaciLLi: evaLuation of oxaLyL-CoA decarboxyLase and formyL-CoA transferase activity in Lactobacillus acidophilus. J Appl Microbiol. 2007;103(5):1600-1609. doi: 10.1111/j.1365-2672.2007.03388.x.</mixed-citation><mixed-citation xml:lang="en">Turroni S., Vitali B., Bendazzoli C., Candela M., Gotti R., Federici F., Pirovano F., Brigid P. Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus. J Appl Microbiol. 2007;103(5):1600-1609. doi: 10.1111/j.1365-2672.2007.03388.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Luo X.Y., Lun Y.Z., Gao W., Hu H.B., Wang Q., Liu Y, Yin J.S., Jiang S.J. Effects of spent cuLture supernatant of Lactobacillus acidophilus on intestinaL fLora in mice with antibiotic- associated diarrhoea. Shijie Huaren Xiaohua Zazhi. 2006;14(19):1870-1873. doi: 10.11569/wcjd.v14.i19.1870.</mixed-citation><mixed-citation xml:lang="en">Luo X.Y., Lun Y.Z., Gao W., Hu H.B., Wang Q., Liu Y., Yin J.S., Jiang SJ. Effects of spent culture supernatant of Lactobacillus acidophilus on intestinal flora in mice with antibiotic- associated diarrhoea. Shijie Huaren Xiaohua Zazhi. 2006;14(19):1870-1873. doi: 10.11569/wcjd.v14.i19.1870.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cani P.D. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716-1725. doi: 10.1136/gutjnL-2018-316723.</mixed-citation><mixed-citation xml:lang="en">Cani P.D. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716-1725. doi: 10.1136/gutjnl-2018-316723.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Храмцов А.Г., Рябцева С.А., Будкевич Р.О., Ахмедова В.Р., Родная А.Б., Маругина Е.В. Пребиотики как функциональные пищевые ингредиенты: терминология, критерии выбора и сравнительной оценки, классификация. Вопросы питания. 2018;87(1):5-17. doi: 10.24411/0042-8833-2018-10001.</mixed-citation><mixed-citation xml:lang="en">Khramtsov A.G., Ryabtseva S.A., Budkevich R.O., Akhmedova V.R., Rodnaya A.B., Marugina E.V. Prebiotics as functional food ingredients: terminology, choice and comparative evaluation criteria, classification. Voprosy pitaniya = Problems of Nutrition. 2018;87(1):5-17. (In Russ.) doi: 10.24411/0042-8833-2018-10001.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pineiro M., Asp N.G., Reid G., MacfarLane S., Morelli L., Brunser O., Tuohy K. FAO technical meeting on prebiotics. J Clin Gastroenterol. 2008;42(3, 2):156-159. doi: 10.1097/MCG.0b013e31817f184e.</mixed-citation><mixed-citation xml:lang="en">Pineiro M.. Asp N.G., Reid G., Macfarlane S.. Morelli L., Brunser O., Tuohy K. FAO technical meeting on prebiotics. J Clin Gastroenterol. 2008;42(3; 2):156-159. doi: 10.1097/MCG.0b013e31817f184e.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3):830-837. doi: 10.1093/jn/137.3.830S.</mixed-citation><mixed-citation xml:lang="en">Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137(3):830-837. doi: 10.1093/jn/137.3.830S.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Буторова Л.И. Новые возможности профилактики и лечения хронического запора комплексными пребиотическими препаратами: выбор оптимального сочетания. Гастроэнтерология Санкт-Петербурга. 2012;(4):2-10. Режим доступа: http://gastroforum.ru/wp-content/uploads/2013/06/GSP_4_2012_P1-26_2-10.pdf.</mixed-citation><mixed-citation xml:lang="en">Butorova L.I. New opportunities for the prevention and treatment of chronic constipation with complex prebiotic drugs: choice of optimal combination. Gastroehnterologiia Sankt-Peterburga = Gastroenterology of St. Petersburg. 2012;(4):2-10. (In Russ.) Available at: http://gastroforum.ru/wp-content/uploads/2013/06/GSP_4_2012_P1-26_2-10.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Guess N.D., Dornhorst A., Oliver N., Bell J.D., Thomas E.L., Frost G.S. A randomized controlled trial: the effect of inulin on weight management and ectopic fat in subjects with prediabetes. Nutr Metab (Lond). 2015;12:36. doi: 10.1186/s12986-015-0033-2.</mixed-citation><mixed-citation xml:lang="en">Guess N.D., Dornhorst A., Oliver N., Bell J.D., Thomas E.L., Frost G.S. A randomized controlled trial: the effect of inulin on weight management and ectopic fat in subjects with prediabetes. Nutr Metab (Lond). 2015;12:36. doi: 10.1186/s12986-015-0033-2.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Копылова Д.В., Кошелев П.И. Возможности применения масляной кислоты и инсулина в раннем восстановительном периоде после холецистэктомии. Лечащий врач. 2013(2):121-125. Режим доступа: https://www.lvrach.ru/2013/02/15435641/.</mixed-citation><mixed-citation xml:lang="en">Kopylova D.V., Koshelev PI. Opportunities of butyric acid and inulin use in the early restoration period after kholetsistektomii. Lechashchiy vrach = Attending Doctor. 2013(2):121-125. (In Russ.) Available at: https://www. lvrach.ru/2013/02/15435641/.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Degnan PH., Taga M.E., Goodman A.L. Vitamin B12 as a Modulator of Gut Microbial Ecology. Cell Metabolism. 2014;20(5):769-778. doi: 10.1016/j.cmet.2014.10.002.</mixed-citation><mixed-citation xml:lang="en">Degnan PH., Taga M.E., Goodman A.L. Vitamin B12 as a Modulator of Gut Microbial Ecology. Cell Metabolism. 2014;20(5):769-778. doi: 10.1016/j.cmet.2014.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Keller S., Ruetz M., Kunze C., Krautler B., Diekert G., Schubert T. Exogenous 5,6-dimethylbenzimidazole caused production of a nonfunctional tetrachloroethene reductive dehalogenase in Sulfurospirillum multivorans. Environ Microbiol. 2014;16(11):3361-3369. doi: 10.1111/1462-2920.12268.</mixed-citation><mixed-citation xml:lang="en">Keller S., Ruetz M., Kunze C., Krautler B., Diekert G., Schubert T. Exogenous 5,6-dimethylbenzimidazole caused production of a nonfunctional tetrachloroethene reductive dehalogenase in Sulfurospirillum multivorans. Environ Microbiol. 2014;16(11):3361-3369. doi: 10.1111/1462-2920.12268.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen MJ., Rasmussen M.R., Andersen C.B., Nexo E., Moestrup S.K. Vitamin B12 transport from food to the body's cells—a sophisticated, multistep pathway. Nature Rev Gastroenterol Hepatol. 2012;(9):345-354. doi: 10.1038/nrgastro.2012.76.</mixed-citation><mixed-citation xml:lang="en">Nielsen MJ., Rasmussen M.R., Andersen C.B., Nexo E., Moestrup S.K. Vitamin B12 transport from food to the body's cells-a sophisticated, multistep pathway. Nature Rev Gastroenterol Hepatol. 2012;(9):345-354. doi: 10.1038/nrgastro.2012.76.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Men Y., Seth E.C., Yi S., Crofts T.S., Allen R.H., Taga M.E., Alvarez-Cohen L. Identification of specific corrinoids reveals corrinoid modification in dechlorinating microbial communities. Environ Microbiol. 2015;17(12):4873-4884. doi: 10.1111/1462-2920.12500.</mixed-citation><mixed-citation xml:lang="en">Men Y., Seth E.C., Yi S., Crofts T.S., Allen R.H., Taga M.E., Alvarez-Cohen L. Identification of specific corrinoids reveals corrinoid modification in dechlorinating microbial communities. Environ Microbiol. 2015;17(12):4873-4884. doi: 10.1111/1462-2920.12500.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Degnan PH., Barry N.A., Mok K.C., Taga M.E., Goodman A.L. Human gut microbes use multiple transporters to distinguish vitamin B12 analogs and compete in the gut. Cell Host Microbe. 2014;15(1):47-57. doi: 10.1016/j.chom.2013.12.007.</mixed-citation><mixed-citation xml:lang="en">Degnan PH., Barry N.A., Mok K.C., Taga M.E., Goodman A.L. Human gut microbes use multiple transporters to distinguish vitamin B12 analogs and compete in the gut. Cell Host Microbe. 2014;15(1):47-57. doi: 10.1016/j.chom.2013.12.007.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ших Е.В., Махова А.А. Витамины в клинической практике: научнопрактическое издание. М.: Практическая медицина; 2014. 367 с. Режим доступа: https://www.elibrary.ru/item.asp?id=25878355.</mixed-citation><mixed-citation xml:lang="en">Shikh E.V., Makhova A.A. Vitamins in clinical practice: a scientific and practical edition. Moscow: Prakticheskaya meditsina; 2014. 367 p. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=25878355.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Громова О.А., Торшин И.Ю., Гусев Е.И. Синергидные нейропротекторные эффекты тиамина, пиридоксина и цианокобаламина в рамках протеома человека. Фармакокинетика и фармакодинамика. 2017;(1):40-51. Режим доступа: https://www.pharmacokinetica.ru/jour/article/view/7/7.</mixed-citation><mixed-citation xml:lang="en">Gromov O.A., Torshin I.Yu., Gusev E.I. Synergistic neuroprotective effects of thiamine, pyridoxine and cyanocobalamin on the level of human pro-teome. Farmakokinetika i farmakodinamika = Pharmacokinetics and Pharmacodynamics. 2017;(1):40-51. (In Russ.) Available at: https://www.pharmacokinetica.ru/jour/article/view/7/7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
